River & Mercantile Asset Management LLP lowered its position in Endo International PLC (NASDAQ:ENDP) (TSE:ENL) by 46.8% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 294,931 shares of the company’s stock after selling 259,904 shares during the period. River & Mercantile Asset Management LLP owned 0.13% of Endo International worth $4,962,000 at the end of the most recent quarter.
A number of other hedge funds have also recently made changes to their positions in ENDP. Comerica Bank raised its position in shares of Endo International by 35.6% in the second quarter. Comerica Bank now owns 214,561 shares of the company’s stock valued at $2,324,000 after buying an additional 56,354 shares in the last quarter. New York State Teachers Retirement System raised its position in shares of Endo International by 27.0% in the second quarter. New York State Teachers Retirement System now owns 356,957 shares of the company’s stock valued at $3,366,000 after buying an additional 75,844 shares in the last quarter. Alps Advisors Inc. raised its position in shares of Endo International by 9.6% in the second quarter. Alps Advisors Inc. now owns 501,708 shares of the company’s stock valued at $4,731,000 after buying an additional 43,791 shares in the last quarter. Sivik Global Healthcare LLC acquired a new stake in shares of Endo International in the second quarter valued at approximately $1,697,000. Finally, Rhumbline Advisers raised its position in shares of Endo International by 18.1% in the second quarter. Rhumbline Advisers now owns 403,885 shares of the company’s stock valued at $3,809,000 after buying an additional 61,884 shares in the last quarter. Institutional investors own 96.63% of the company’s stock.
ENDP has been the subject of a number of analyst reports. Mizuho lifted their price target on shares of Endo International to $17.00 and gave the company a “neutral” rating in a research report on Tuesday, August 14th. TheStreet upgraded shares of Endo International from a “d” rating to a “c-” rating in a research report on Monday, August 20th. Zacks Investment Research upgraded shares of Endo International from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research report on Monday, September 24th. Cantor Fitzgerald lifted their price target on shares of Endo International from $12.00 to $18.00 and gave the company a “neutral” rating in a research report on Friday, October 19th. Finally, Canaccord Genuity upgraded shares of Endo International from a “hold” rating to a “buy” rating and lifted their price target for the company from $16.00 to $20.00 in a research report on Friday, November 9th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $15.32.
Shares of NASDAQ:ENDP opened at $11.57 on Friday. The company has a market capitalization of $2.60 billion, a P/E ratio of 3.01, a PEG ratio of 4.25 and a beta of 0.35. Endo International PLC has a 1 year low of $5.27 and a 1 year high of $18.50.
Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings data on Thursday, November 8th. The company reported $0.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.12. The business had revenue of $745.00 million for the quarter, compared to analysts’ expectations of $694.93 million. Endo International had a negative net margin of 37.82% and a positive return on equity of 1,348.52%. The firm’s quarterly revenue was down 5.3% compared to the same quarter last year. During the same period last year, the firm posted $0.91 earnings per share. On average, equities analysts anticipate that Endo International PLC will post 2.73 EPS for the current fiscal year.
In related news, Director Nancy J. Hutson sold 10,000 shares of Endo International stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $12.83, for a total value of $128,300.00. Following the transaction, the director now directly owns 49,970 shares of the company’s stock, valued at $641,115.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.80% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “River & Mercantile Asset Management LLP Decreases Holdings in Endo International PLC (ENDP)” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/12/08/river-mercantile-asset-management-llp-decreases-holdings-in-endo-international-plc-endp.html.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Read More: What is a Reverse Stock Split?
Want to see what other hedge funds are holding ENDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endo International PLC (NASDAQ:ENDP) (TSE:ENL).
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.